Geometry Dash APK Hill Climb Racing APK
68.1 F
New York
Wednesday, October 4, 2023

Sangamo Therapeutics Inc. (NASDAQ:SGMO) Recent Earnings Shows Major Promise

Must read

Sangamo Therapeutics Inc. (SGMO) shares are trading at higher $10.09 and the avg recommendation for the stock is Moderate Buy.

To add more color to this target, the company’s high over the last year is $13.20 and the low is $4.81. Over the last 52 weeks, SGMO is down -5.61% while the S&P 500 is up 17.45%. The catalyst for this interesting swing was the company’s recent earnings report.

A Notable Earnings Report

In the last quarter, SGMO reported a profit of $61.46 million. Sangamo Therapeutics Inc. also saw revenues increase to $57.76 million. In addition, SGMO has free cash flow of $163.47 million as of 09-2020. The company’s EBITDA came in at -$0.62 million which compares well with its peers.

SGMO booked profit margins of -51.50%, its Return on Equity (ROE) is -16.30%, and its Return on Assets is -9.80%. All told, it is clear that, SGMO needs to be on your watchlist.

Find out when SGMO reaches critical levels. Subscribe to Right Now by entering your Email in the box below.

Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. SGMO has a short ratio of 12.85 and outstanding shares of 141.10M.

Company Outlook

SGMO has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 1.48 million and more growth is possible in the weeks ahead. Traders will also note the company’s earnings per share came in at -0.60. Sangamo Therapeutics Inc. SGMO also noted assets of $963.71 million at the end of the last quarter. Investors should also keep an eye on sector updates as SGMO has historically followed its peers on positive news.

All told, Sangamo Therapeutics Inc. SGMO has strung together solid data and demonstrated underlying fundamentals. At its current valuation, SGMO represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.

Sangamo Therapeutics Inc. SGMO is now commanding a market cap of 1.38B and a float of 116.55M. SGMO is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of SGMO stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in SGMO, either long or short, and we have not been compensated for this article.

Latest article